Feedback on FDA draft guidance on considerations for the development of CAR-T cell products 

Chimeric antigen receptor (CAR) T cell products are human gene therapy products in which the T cell specificity is genetically modified to enable recognition of a desired target antigen for therapeutic purposes. This draft FDA guidance is intended to assist sponsors, including industry and academic sponsors, developing CAR T cell products. In this guidance the FDA provide CAR T cell specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and clinical study design. Recommendations specific to autologous or allogeneic CAR T cell products are noted in this guidance. It also provides recommendations for analytical comparability studies for CAR T cell products.  BioPhorum CGT Regulatory Strategy workstream members provide feedback on the draft.

This document is reserved for the use of BioPhorum members only.

I don't have access to this document

Make a selection below and submit your request. We will get back to you ASAP.

My company would like to become a member

If you're not sure if your company is a member of this Phorum, or if you would like to enquire on behalf of your company about becoming a member, please see our membership page.